Health Care
Biosimilars
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
Commentary
The FDA’s sunscreen rules leave Americans exposed
Just in time for the beginning of summer, the Food and Drug Administration has approved a new sunscreen ingredient for the first time in more than a quarter-century. Bemotrizinol is a next-generation ultraviolet filter already widely used in other nations. The FDA fully approved the ingredient for use in the ...
Commentary
Congress should fulfill this drug program’s promise to vulnerable Californians
A federal program intended to help low-income patients has instead become a major revenue source for large California hospital systems. Hospitals are using gaps in oversight within the 340B Drug Pricing Program to lock in substantial margins on prescription drugs — and driving healthcare costs higher for Californians in the ...
Commentary
Canada’s Assisted-Suicide Boom Reveals the Human Costs of Single-Payer
In Canada, access to medical care can take months. Access to assisted suicide, however, is much easier to come by. Ten years ago today, Canada’s Medical Assistance in Dying (MAID) program was legalized, and this year, Canada is on track to surpass 100,000 assisted-suicide deaths. Earlier this year, an Ontario ...
Commentary
This Drug Patent Bill Would Hurt Innovation Without Lowering Prices
This week, the Senate Committee on Health, Education, Labor and Pensions will consider several bills that aim to “make health care more affordable and accessible to American families.” One in particular deserves a closer look. The Medication Affordability and Patent Integrity Act, introduced by Sen. Maggie Hassan, D-N.H., and co-sponsored ...
Commentary
Obamacare’s Enrollment Figures Deserve A Closer Look
Enrollment on the Obamacare exchanges is falling for the first time in years. The exchanges launched on January 1, 2014—nearly four years after President Obama signed the Affordable Care Act into law on March 23, 2010. A new analysis from KFF estimates that the number of people enrolled in an ...
Commentary
Trump Should Stand Firm Against Europe’s Drug Price Free-Riders
For decades, wealthy foreign governments have left it to Americans to pay for pharmaceutical innovation — and then insisted on enjoying the fruits of that innovation at a discount. President Trump has begun challenging that status quo through trade negotiations designed to pressure foreign countries into paying more for innovative ...
Drug Innovation
Unauthorized GLP-1 Knockoffs Risk Patient Safety and Future Innovation, New PRI Brief Warns
As federal regulators intensify enforcement against companies selling unauthorized knockoffs of blockbuster weight-loss drugs, a new Pacific Research Institute brief warns that the booming GLP-1 knockoff market is creating patient safety risks while undermining future breakthrough medicines. “GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling ...
Commentary
Medicaid’s fraud problem has become impossible to ignore
The House Energy and Commerce Committee is demanding records from 11 states as part of a widening investigation into potential Medicaid fraud. It’s just the latest sign that Washington is beginning to recognize the scale of abuse inside one of the nation’s largest entitlement programs. The Centers for Medicare and ...
Commentary
Americans Get Medicines First – Why?
Americans hear a lot these days about how Europe has healthcare all figured out. Progressives love pointing to countries like Britain, France, and Canada as models America should follow — especially when it comes to prescription drug prices. What they rarely mention is the price those countries pay for government-controlled ...
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
The FDA’s sunscreen rules leave Americans exposed
Just in time for the beginning of summer, the Food and Drug Administration has approved a new sunscreen ingredient for the first time in more than a quarter-century. Bemotrizinol is a next-generation ultraviolet filter already widely used in other nations. The FDA fully approved the ingredient for use in the ...
Congress should fulfill this drug program’s promise to vulnerable Californians
A federal program intended to help low-income patients has instead become a major revenue source for large California hospital systems. Hospitals are using gaps in oversight within the 340B Drug Pricing Program to lock in substantial margins on prescription drugs — and driving healthcare costs higher for Californians in the ...
Canada’s Assisted-Suicide Boom Reveals the Human Costs of Single-Payer
In Canada, access to medical care can take months. Access to assisted suicide, however, is much easier to come by. Ten years ago today, Canada’s Medical Assistance in Dying (MAID) program was legalized, and this year, Canada is on track to surpass 100,000 assisted-suicide deaths. Earlier this year, an Ontario ...
This Drug Patent Bill Would Hurt Innovation Without Lowering Prices
This week, the Senate Committee on Health, Education, Labor and Pensions will consider several bills that aim to “make health care more affordable and accessible to American families.” One in particular deserves a closer look. The Medication Affordability and Patent Integrity Act, introduced by Sen. Maggie Hassan, D-N.H., and co-sponsored ...
Obamacare’s Enrollment Figures Deserve A Closer Look
Enrollment on the Obamacare exchanges is falling for the first time in years. The exchanges launched on January 1, 2014—nearly four years after President Obama signed the Affordable Care Act into law on March 23, 2010. A new analysis from KFF estimates that the number of people enrolled in an ...
Trump Should Stand Firm Against Europe’s Drug Price Free-Riders
For decades, wealthy foreign governments have left it to Americans to pay for pharmaceutical innovation — and then insisted on enjoying the fruits of that innovation at a discount. President Trump has begun challenging that status quo through trade negotiations designed to pressure foreign countries into paying more for innovative ...
Unauthorized GLP-1 Knockoffs Risk Patient Safety and Future Innovation, New PRI Brief Warns
As federal regulators intensify enforcement against companies selling unauthorized knockoffs of blockbuster weight-loss drugs, a new Pacific Research Institute brief warns that the booming GLP-1 knockoff market is creating patient safety risks while undermining future breakthrough medicines. “GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling ...
Medicaid’s fraud problem has become impossible to ignore
The House Energy and Commerce Committee is demanding records from 11 states as part of a widening investigation into potential Medicaid fraud. It’s just the latest sign that Washington is beginning to recognize the scale of abuse inside one of the nation’s largest entitlement programs. The Centers for Medicare and ...
Americans Get Medicines First – Why?
Americans hear a lot these days about how Europe has healthcare all figured out. Progressives love pointing to countries like Britain, France, and Canada as models America should follow — especially when it comes to prescription drug prices. What they rarely mention is the price those countries pay for government-controlled ...